2014 | | Liver X receptors alpha gene (NR1H3) promoter polymorphisms are associated with systemic lupus erythematosus in Koreans. | 김현아, 서창희, 전자영 |
2024 | | Longitudinal assessment of urinary ALCAM, HPX, and PRDX6 in Korean patients with systemic lupus erythematosus: implications for disease activity monitoring and treatment response | 김지원, 김현아, 백욱영, 서창희, 정주양 |
2021 | | Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus | 서창희 |
2019 | | Mindfulness-based cognitive therapy in Korean patients with systemic lupus erythematosus: A pilot study | 김현아, 서창희, 정주양, 조선미 |
2020 | | Obesity increases the incidence of new-onset lupus nephritis and organ damage during follow-up in patients with systemic lupus erythematosus | 김현아 |
2018 | | Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil | 김현아, 서창희 |
2016 | | Perceived and actual risk of cardiovascular disease in patients with rheumatoid arthritis in Korea: A cross-sectional study | 부선주, 서창희, 정주양 |
2019 | | Polymorphisms of MFGE8 are associated with susceptibility and clinical manifestations through gene expression modulation in Koreans with systemic lupus erythematosus | 김현아, 서창희, 정주양 |
2016 | | Polymorphisms of the TRPV2 and TRPV3 genes associated with fibromyalgia in a Korean population | 김현아 |
2010 | | Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. | 김현아, 서창희 |
2020 | | Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry | 김현아 |
2020 | | Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry | 김현아 |
2020 | | Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry | 김현아 |
2015 | | Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines. | 서창희 |
2015 | | Role of bone scan in the assessment of polymyositis/dermatomyositis. | 김현아, 서창희, 안영실, 정주양 |
2016 | | Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research | 서창희, 정주양 |
2020 | | Seasonal Variations and Associated Factors of Gout Attacks: a Prospective Multicenter Study in Korea | 김현아, 서창희, 정주양 |
2015 | | Seasonality of gout in Korea: a multicenter study. | 김현아, 서창희 |
2013 | | Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. | 김현아, 서창희, 전자영, 정주양 |
2014 | | Serum growth arrest-specific protein 6 levels are elevated in adult-onset Still's disease. | 김현아, 서창희, 전자영, 정주양 |
2016 | | Severity of fibromyalgia symptoms is associated with socioeconomic status and not obesity in Korean patients | 김현아 |
2019 | | Standardized, musculoskeletal ultrasonographic reference values for healthy Korean adults | 김현아 |
2017 | | Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry | 김현아, 서창희 |
2017 | | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry | 김현아 |
2013 | | The interleukin 6 receptor alpha gene polymorphisms are associated with clinical manifestations of systemic lupus erythematosus in Koreans. | 김현아, 서창희, 전자영 |
2012 | | Therapeutic responses and prognosis in adult-onset Still's disease | 김현아, 서창희 |
2018 | | Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea | 서창희 |
2022 | | Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis | 서창희 |